Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke visit Proactive's London studio to speak with Thomas Warner after releasing final results for 2022.
They explain why they believe 2022 was a "transformational" year for the Group, before looking ahead to what investors can expect next.
Lee says that Tissue Regenix is "in the process of getting the regulatory approvals" to enable it to sell its products in markets beyond the US.